MedTrace Logo

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

NCT05177731 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-10-03

No results posted yet for this study

Summary

This research is being done to assess the therapeutic efficacy and safety of a promising (venetoclax and decitabine) versus conventional "7+3"chemotherapy in induction young patients with acute myeloid leukemia.

This study involves the following:

Venetoclax and decitabine (investigational combination) Cytarabine and idarubicin (per standard of care)

Conditions

  • AML, Adult
  • Chemotherapy Effect

Interventions

DRUG

Venetoclax

Orally by mouth

DRUG

Decitabine for Injection

Intravenous infusion

DRUG

Cytarabine

Intravenous infusion

DRUG

Idarubicin

Intravenous infusion

DRUG

Gilteritinib

Orally by mouth

Sponsors & Collaborators

  • Chen Suning

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-02-28
Completion
2024-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177731 on ClinicalTrials.gov